Search

Displaying all 2 results
DrugBest match

Nilotinib

go.drugbank.com/drugs/DB04868
ApprovedInvestigational

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant ...

  1. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those that target the inactive kinase domain ([imatinib], [nilotinib

    Categories: Nicotinic Acids